ArticlePLoS computational biology2026
A unified framework for potency-oriented AMP discovery via multi-modal learning and guided sequence synthesis.
Article in PLoS computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The rapid emergence of drug-resistant pathogens poses a critical threat to global health. With traditional antibiotics losing efficacy, antimicrobial peptides (AMPs) have gained attention for their unique mechanisms and lower resistance potential. We aimed to accelerate AMP discovery by proposing a closed-loop framework that combines AMP-Hunter (a shared-architecture discriminator for AMP classification and MIC prediction that integrates convolutional neural networks with graph neural networks), and AMP-Forge (a generator integrating multiple sequence alignment to select original candidates) and is guided by minimum inhibitory concentration (MIC)for latent space optimization and candidate selection. AMP-Hunter outperformed baseline models in both AMP classification and MIC prediction, achieving 95.82% accuracy and a 95.80% F1 score on the test set for classification, and an R2 of 0.9245 with an MAE of 0.2305 for MIC prediction. Guided by its predictions, AMP-Forge generated peptide sequences with lower MIC values and improved physicochemical properties associated with antimicrobial activity. Molecular dynamics simulations further provided in silico evidence supporting the antimicrobial potential of selected sequences by identifying stable membrane disruption and insertion behaviors consistent with membrane-targeting activity. Thus, the generation-screening-validation workflow enables reliable discovery of potent AMPs, and provides a practical strategy for rational peptide design, rapid prediction, and translational applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.